Your browser doesn't support javascript.
loading
Connective tissue growth factor as a novel therapeutic target in high grade serous ovarian cancer.
Moran-Jones, Kim; Gloss, Brian S; Murali, Rajmohan; Chang, David K; Colvin, Emily K; Jones, Marc D; Yuen, Samuel; Howell, Viive M; Brown, Laura M; Wong, Carol W; Spong, Suzanne M; Scarlett, Christopher J; Hacker, Neville F; Ghosh, Sue; Mok, Samuel C; Birrer, Michael J; Samimi, Goli.
Afiliación
  • Moran-Jones K; Kinghorn Cancer Centre and Garvan Institute of Medical Research, Cancer Research Program, Darlinghurst, NSW, Australia.
  • Gloss BS; St. Vincent's Clinical School, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia.
  • Murali R; Kinghorn Cancer Centre and Garvan Institute of Medical Research, Cancer Research Program, Darlinghurst, NSW, Australia.
  • Chang DK; St. Vincent's Clinical School, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia.
  • Colvin EK; Department of Pathology and The Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
  • Jones MD; Kinghorn Cancer Centre and Garvan Institute of Medical Research, Cancer Research Program, Darlinghurst, NSW, Australia.
  • Yuen S; Kolling Institute of Medical Research, Royal North Shore Hospital, University of Sydney, Sydney, NSW, Australia.
  • Howell VM; Kinghorn Cancer Centre and Garvan Institute of Medical Research, Cancer Research Program, Darlinghurst, NSW, Australia.
  • Brown LM; Kolling Institute of Medical Research, Royal North Shore Hospital, University of Sydney, Sydney, NSW, Australia.
  • Wong CW; Kolling Institute of Medical Research, Royal North Shore Hospital, University of Sydney, Sydney, NSW, Australia.
  • Spong SM; Kinghorn Cancer Centre and Garvan Institute of Medical Research, Cancer Research Program, Darlinghurst, NSW, Australia.
  • Scarlett CJ; FibroGen Inc., San Francisco, CA, USA.
  • Hacker NF; FibroGen Inc., San Francisco, CA, USA.
  • Ghosh S; Kinghorn Cancer Centre and Garvan Institute of Medical Research, Cancer Research Program, Darlinghurst, NSW, Australia.
  • Mok SC; School of Environmental & Life Sciences, University of Newcastle, Ourimbah, NSW, Australia.
  • Birrer MJ; School of Women's and Children's Health, University of New South Wales, and Gynaecological Cancer Centre, Royal Hospital for Women, Sydney, NSW, Australia.
  • Samimi G; Laboratory of Gynecologic Oncology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Oncotarget ; 6(42): 44551-62, 2015 Dec 29.
Article en En | MEDLINE | ID: mdl-26575166
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Neoplasias Peritoneales / Biomarcadores de Tumor / Células del Estroma / Neoplasias Quísticas, Mucinosas y Serosas / Factor de Crecimiento del Tejido Conjuntivo / Anticuerpos Monoclonales / Antineoplásicos Tipo de estudio: Prognostic_studies Límite: Aged80 Idioma: En Revista: Oncotarget Año: 2015 Tipo del documento: Article País de afiliación: Australia Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Neoplasias Peritoneales / Biomarcadores de Tumor / Células del Estroma / Neoplasias Quísticas, Mucinosas y Serosas / Factor de Crecimiento del Tejido Conjuntivo / Anticuerpos Monoclonales / Antineoplásicos Tipo de estudio: Prognostic_studies Límite: Aged80 Idioma: En Revista: Oncotarget Año: 2015 Tipo del documento: Article País de afiliación: Australia Pais de publicación: Estados Unidos